Postal address:
Norwegian Institute of Public Health
WHO Collaborating Centre for Drug Statistics Methodology
Postboks 222 Sk°yen
0213 Oslo

Visiting/delivery address:
Myrens verksted 6H
0473 Oslo

Tel:  +47 21 07 81 60

New search    Hide text from Guidelines


The group is divided into therapeutic subgroups:
N05A - Antipsychotics
N05B - Anxiolytics
N05C - Hypnotics and sedatives


This group comprises preparations used in the treatment of neuroses and psychosomatic disorders associated with anxiety and tension, e.g. benzodiazepines.
See also:
N05A - Antipsychotics
N05C - Hypnotics and sedatives
Usually the presence of an anxiolytic (or other psycholeptics) in combined preparations must be regarded as being of secondary importance and the preparations should be classified in the respective therapeutic groups (e.g. A03C - Antispasmodics in combination with psycholeptics, N02 - Analgesics).
Combined preparations used mainly for the treatment of anxiety are classified at separate 5th levels using the corresponding 50-series.
The group is subdivided according to chemical structure.

The DDDs are based on the treatment of anxiety.

N05BA Benzodiazepine derivatives

Benzodiazepines used mainly in the treatment of sleep disturbances are classified in N05C - Hypnotics and sedatives.
Clonazepam used in the treatment of epilepsy is classified in N03 - Antiepileptics.

The parenteral DDD for chlordiazepoxide is higher than the oral DDD due to lower bioavailability for intramuscular injections.

N05BB Diphenylmethane derivatives
N05BC Carbamates
N05BD Dibenzo-bicyclo-octadiene derivatives
N05BE Azaspirodecanedione derivatives
N05BX Other anxiolytics

This group comprises anxiolytics which cannot be classified in the preceding groups.

Last updated: 2024-01-26